Press Room

Event

Webinar: High performance solutions for DPI delivery: new formulation and device platforms

Start
Wednesday, October 04, 2023 - 16:00
Location: online

October 4th, 2023

11:00 am EDT | 4:00 pm GMT | 5:00 pm CEST | 8:00 am PDT

Registrations to the webinar are subject to approval.

 

Watch on-demand.

 

Featured Hovione experts in this webinar
Webinar_Inhalation_Sunriser_Speaker Susana Saldanha | Hovione

 
Webinar_Inhalation_Sunriser_Speaker Sofia Silva | Hovione

 
Susana Saldanha, M.Sc.

R&D Manager, Inhalation and Advanced Drug Delivery		 Sofia Silva, M.Sc.

R&D Manager, Analytical Development

 

This webinar will address the most relevant solutions for dry powder inhaler (DPI) development covering both formulation and device development, as well as process optimization and analytical characterization, under an integrated development approach. 

DPIs are the dosage form of choice for delivering high doses of inhaled drugs and achieving maximum delivery efficiency to patients. This presentation will focus on new formulation platforms, aiming to address the pharmacokinetics requirements of the target drug and indication, coupled with a new high performance, high-dose device platform, the Sunriser® DPI. 

This integrated approach is designed to maximize drug delivery efficiency while maintaining safety, and is able to address a diversified array of diseases.

 

Key Learning Objectives:

  • Gain insights on novel formulation development strategies for DPIs, to be able to improve drug delivery efficiency even with high drug loads;
  • Understand the potential of wet milling and dry milling capabilities for boosting the fine particle dose of DPI formulations;
  • Discover analytical characterization techniques, for differentiated formulations, to further understand product properties that impact drug delivery and aerodynamic performance;
  • Understand features associated with a novel high efficiency device platform, the Sunriser® capsule-based Dry Powder Inhaler;
  • Network with industry peers and experts during the live Q&A session.



Who Should Attend:

  • Pharmaceutical researchers and scientists
  • CMC experts on inhalation drug delivery
  • Business development, portfolio management and technology licensing experts
  • Inhalation product development professionals
  • Respiratory therapeutics specialists

     

Watch on-demand.

Our experts will reply to your questions during the live Q&A session.

 



 

Also in the Press Room

See All

Every year, the largest bank in Portugal, Caixa Geral de Depósitos recognizes some of Portugal’s brightest young minds through the Caixa +Mundo Awards, providing nearly €800,000 in scholarships to students as they pursue higher education. In this year´s edition, Caixa named the award bestowed upon students pursuing science for Diane Villax. This prestigious honor places Diane Villax among the award’s namesakes – a distinguished group of prominent personalities who have made notable contributions to Portugal´s socio-economic, cultural, political and scientific development over the last 50 years, such as António Ramalho Eanes, Mário Soares, José Saramago, Sophia de Mello Breyner, Leonor Beleza, Elvira Fortunato, Rui Nabeiro, Américo Amorim, and José Manuel de Mello. Diane Villax will also honor the seven scientific award winners by personally meeting with each of them, and following their journeys as future innovators and leaders. But this honor is about far more than one individual. It is a celebration of an entire organization and the people behind it. For 67 years, generations of dedicated teams have worked together with passion, purpose, and excellence to manufacture life-saving medicines and advance science that has a real impact on people. This recognition belongs to all of us.    

News

Prestigious Caixa +Mundo Award named in honor of Diane Villax

May 14, 2026

CDMO Hovione and Industrial Design Consultancy (IDC) have announced that their new single-use capsule-based nasal delivery device is now available exclusively as part of an integrated platform that includes Hovione’s intranasal drug development and manufacturing services. The companies partnered in 2023 with plans for development of two capsule-based devices for intranasal delivery: the single-use device and a multidose device. Read the full article at OINDPnews.com      

Press Clipping
OINDP - Orally inhaled and nasal drug products news, May 11, 2026

Hovione and IDC announce new single-use capsule-based intranasal delivery device for dry powder formulations

May 11, 2026

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping
Contract Pharma, 7 May 2026

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026

Also in Events

See All